Low-Dose Aspirin Assessed for Cognitive Decline Protection

This article originally appeared here.
Review of large studies found no protection against dementia
Review of large studies found no protection against dementia

HealthDay News — Low-dose aspirin does not protect against cognitive decline, according to a review published April 20 in the Journal of the American Geriatrics Society.

Nicola Veronese, MD, from the Italian Research Council in Padova, and colleagues conducted a systematic literature review to identify observational and interventional studies that investigated low-dose aspirin and the incidence of dementia and cognitive impairment.

The researchers identified 8 studies (36,196 participants). Over a median of 6 years of follow-up, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment (5 studies; 26,159 participants; odds ratio, 0.82; 95% confidence interval, 0.55 to 1.22; P=0.33), after adjusting for a median of 3 potential confounders. In 3 randomized controlled trials (10,037 participants; median follow-up, 5 years), the use of low-dose aspirin in individuals without dementia was not associated with significantly better global cognition (standardized mean difference, 0.005; 95% confidence interval, −0.04 to 0.05; P=0.84). 

Related Articles

"This review found no evidence that low-dose aspirin buffers against cognitive decline or dementia or improves cognitive test scores in randomized controlled trials," the authors write.

Abstract
Full Text (subscription or payment may be required)